Australians will soon have another option for weight loss, after the Therapeutic Goods Administration (TGA) approved a new daily pill called Foundayo.
The medication, made by pharmaceutical company Lilly, belongs to a class of drugs known as GLP-1, which includes Ozempic and Wegovy.
These medicines work by mimicking a natural hormone that helps control hunger and slow digestion, making people feel fuller for longer.
Unlike some existing treatments, Foundayo can be taken at any time of the day, without restrictions around food or water.
Associate Professor Samantha Hocking, president of the National Association of Clinical Obesity Services, said the approval could help address Australia’s growing obesity problem.
“Australia is grappling with rising rates of overweight and obesity, which now affect around 13 million adults,” Hocking said.
“Obesity is a complex chronic disease that increases the risk of at least 30 other serious medical conditions, ranging from cancer and cardiovascular disease to type 2 diabetes..
“The impact of obesity and type 2 diabetes on individuals, families and our health system highlights the urgent need for stronger prevention efforts and improved access to clinically proven treatment options.”
Lilly Australia said the approval followed more than a decade of research, with clinical trials involving more than 10,000 people across 15 countries, including Australia.
“Now that Foundayo can be prescribed, our focus is on ways to deliver broader access for Australians who may benefit from this new medicine,” Lilly Australia general manager Dr Manny Simons said.
Foundayo is available by private prescription but has not been added to the Pharmaceutical Benefits Scheme (PBS), meaning patients will need to pay the full cost themselves.
The company warns that the medication should not be taken alongside other GLP-1 drugs. Possible side effects include digestive problems, which were generally mild or moderate in clinical trials.
It also carries warnings about low blood sugar when used with certain diabetes medicines, pancreatitis and possible interactions with other medications. It should not be used during pregnancy.
Foundayo is the latest GLP-1 drug to receive TGA approval, following the recent approval of a Wegovy pill.
Image: Shutterstock











